{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:08Z","timestamp":1784599328480,"version":"3.55.0"},"reference-count":44,"publisher":"ARAN Ediciones","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.hipert.2016.05.003","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T22:50:03Z","timestamp":1467154203000},"page":"150-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilidad de la espironolactona en el manejo farmacol\u00f3gico de la hipertensi\u00f3n arterial resistente. Comentarios sobre el estudio Pathway-2"],"prefix":"10.20960","volume":"33","author":[{"given":"J.C.","family":"Prado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2016.05.003_bib0225","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension."},{"key":"10.1016\/j.hipert.2016.05.003_bib0230","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"De la Sierra","year":"2011","journal-title":"Hypertension."},{"key":"10.1016\/j.hipert.2016.05.003_bib0235","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ajh\/hpu151","article-title":"Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations","volume":"28","author":"Achelrod","year":"2015","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0240","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomized, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.hipert.2016.05.003_bib0245","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jash.2011.08.003","article-title":"Validation of therapeutic scheme for the treatment of resistant hypertension","volume":"5","author":"Segura","year":"2011","journal-title":"J Am Soc Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0250","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardized antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomized controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.hipert.2016.05.003_bib0255","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3949\/ccjm.82a.14091","article-title":"Diuretics for hypertension: Hydrochlorothiazide or chlorthalidone?","volume":"82","author":"Cooney","year":"2015","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.hipert.2016.05.003_bib0260","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","article-title":"Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone antihypertensive and metabolic effects","volume":"65","author":"Roush","year":"2015","journal-title":"Hypertension."},{"key":"10.1016\/j.hipert.2016.05.003_bib0265","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0002-9149(76)90409-4","article-title":"Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity","volume":"37","author":"Karlberg","year":"1976","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.hipert.2016.05.003_bib0270","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cpt1978245525","article-title":"Antihypertensive responses to spironolactone in normal renin hypertension","volume":"24","author":"Ogilvie","year":"1978","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.hipert.2016.05.003_bib0275","first-page":"31","article-title":"Comparison of chlorthalidone and spironolactone in low-renin essential hypertension","volume":"128","author":"Kreeft","year":"1983","journal-title":"Can Med Assoc J."},{"key":"10.1016\/j.hipert.2016.05.003_bib0280","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.hipert.2016.05.003_bib0285","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/endo-118-2-819","article-title":"Intracerebroventricular infusion of aldosterone induces hypertension in rats","volume":"118","author":"G\u00f3mez-S\u00e1nchez","year":"1986","journal-title":"Endocrinology."},{"key":"10.1016\/j.hipert.2016.05.003_bib0290","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Lond)."},{"key":"10.1016\/j.hipert.2016.05.003_bib0295","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","article-title":"Aldosterone induces contraction of the resistance arteries in man","volume":"166","author":"Romagni","year":"2003","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.hipert.2016.05.003_bib0300","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00000441-198912000-00001","article-title":"Plasma volume in resistant hypertension: Guide to pathophysiology and therapy","volume":"298","author":"Graves","year":"1989","journal-title":"Am J Med Sci."},{"key":"10.1016\/j.hipert.2016.05.003_bib0305","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/dc07-0031","article-title":"Primary aldosteronism in diabetic subjects with resistant hypertension","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care."},{"key":"10.1016\/j.hipert.2016.05.003_bib0310","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/HJH.0b013e328360ddf6","article-title":"Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China","volume":"31","author":"Sang","year":"2013","journal-title":"J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0315","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11892-014-0516-y","article-title":"Resistant hypertension in diabetes mellitus","volume":"14","author":"Bayliss","year":"2014","journal-title":"Curr Diab Rep."},{"key":"10.1016\/j.hipert.2016.05.003_bib0320","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1210\/jc.2008-0251","article-title":"Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients","volume":"93","author":"Rossi","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.hipert.2016.05.003_bib0325","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: Association between resistant hypertension, aldosterone and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.hipert.2016.05.003_bib0330","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberg","year":"2005","journal-title":"Am Heart J."},{"key":"10.1016\/j.hipert.2016.05.003_bib0335","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.hipert.2016.05.003_bib0340","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0345","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial","volume":"57","author":"Vaclavik","year":"2011","journal-title":"Hypertension."},{"key":"10.1016\/j.hipert.2016.05.003_bib0350","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension: A randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT)","volume":"93","author":"Vaclavik","year":"2014","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.hipert.2016.05.003_bib0355","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0360","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0091270003258189","article-title":"Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?","volume":"43","author":"Prisant","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.hipert.2016.05.003_bib0365","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/HJH.0b013e328332b79b","article-title":"Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO","volume":"28","author":"Parthasarathy","year":"2010","journal-title":"J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0370","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"De Souza","year":"2010","journal-title":"Hypertension."},{"key":"10.1016\/j.hipert.2016.05.003_bib0375","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"Colussi","year":"2013","journal-title":"J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0380","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1345\/aph.1P338","article-title":"Spironolactone management of resistant hypertension","volume":"44","author":"Marrs","year":"2010","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.hipert.2016.05.003_bib0385","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: A prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0390","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"10.1016\/j.hipert.2016.05.003_bib0395","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: A double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0400","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"10.1016\/j.hipert.2016.05.003_bib0405","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jash.2013.12.001","article-title":"Modulation of aldosterone levels by -344C\/T CYP11B2 polymorphism and spironolactone use in resistant hypertension","volume":"8","author":"Fontana","year":"2014","journal-title":"J Am Soc Hypertens."},{"key":"10.1016\/j.hipert.2016.05.003_bib0410","first-page":"7270","article-title":"Clinical efficacy of spironolactone for resistant hypertension: A meta-analysis from randomized controlled clinical trials","volume":"8","author":"Guo","year":"2015","journal-title":"Int J Clin Exp Med."},{"key":"10.1016\/j.hipert.2016.05.003_bib0415","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: A meta-analysis of randomized and nonrandomised studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.hipert.2016.05.003_bib0420","doi-asserted-by":"crossref","DOI":"10.1038\/jhh.2015.122","article-title":"Management of resistant hypertension: Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology","author":"Denolle","year":"2016","journal-title":"J Hum Hypertens."},{"issue":"Suppl R","key":"10.1016\/j.hipert.2016.05.003_bib0425","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.4244\/EIJV9SRA11","article-title":"Updated ESH position paper on interventional therapy of resistant hypertension","volume":"9","author":"Schmieder","year":"2013","journal-title":"EuroIntervention."},{"key":"10.1016\/j.hipert.2016.05.003_bib0430","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.hipert.2016.05.003_bib0435","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","article-title":"Role of adding spironolactone and renal denervation in true resistant hypertension. One year outcomes of randomized PRAGUE-15 Study","volume":"67","author":"Rosa","year":"2016","journal-title":"Hypertension."},{"key":"10.1016\/j.hipert.2016.05.003_bib0440","series-title":"Hypertension: the clinical management of primary hypertension in Adults: Update of clinical Guidelines 18 and 34 [Internet]","year":"2011"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183716300277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183716300277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:14:57Z","timestamp":1784596497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183716300277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1889183716300277"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2016.05.003","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilidad de la espironolactona en el manejo farmacol\u00f3gico de la hipertensi\u00f3n arterial resistente. Comentarios sobre el estudio Pathway-2","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2016.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}